PE20091573A1 - Derivados heterociclicos de urea como inhibidores de adn girasa y/o topoisomerasa - Google Patents

Derivados heterociclicos de urea como inhibidores de adn girasa y/o topoisomerasa

Info

Publication number
PE20091573A1
PE20091573A1 PE2009000289A PE2009000289A PE20091573A1 PE 20091573 A1 PE20091573 A1 PE 20091573A1 PE 2009000289 A PE2009000289 A PE 2009000289A PE 2009000289 A PE2009000289 A PE 2009000289A PE 20091573 A1 PE20091573 A1 PE 20091573A1
Authority
PE
Peru
Prior art keywords
cyane
halo
optionally substituted
urea
alkyl
Prior art date
Application number
PE2009000289A
Other languages
English (en)
Inventor
Shanta Bist
Brian Dangel
Brian Sherer
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40474753&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20091573(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20091573A1 publication Critical patent/PE20091573A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

REFERIDA A UN DERIVADO DE UREA DE FORMULA (I), DONDE X ES N, CH O CR4; R1 ES ALQUILO C1-C6, ALQUENILO C2-C6, ALQUINILO C2-C6, ENTRE OTROS; R2 ES H O ALQUILO C1-C6 OPCIONALMENTE SUSTITUIDO CON HALO CIANO, OH, ENTRE OTROS; R3 ES CARBOCICLILO C3-C14 O HETEROCICLILO OPCIONALMENTE SUSTITUIDO CON R10 O R11; R4 ES HALO, NITRO, CIANO, OH, ENTRE OTROS; R5 ES H O HETEROCICLILO OPCIONALMENTE SUSTITUIDO CON =O, =S O UNO O MAS R14; R6 ES HALO, NITRO, CIANO, OH, AMINO, MERCAPTO, ENTRE OTROS; m ES 0 O 1; p ES 0, 1, 2 O 3; EL ANILLO B ES CARBOCICLILO C3-C14 O HETEROCICLILO OPCIONALMENTE SUSTITUIDO CON R15, OXO; R10 Y R14 SON HALO, NITRO, CIANO, OH, AMINO, ENTRE OTROS; R11 Y R15 SON ALQUILO C1-C6, CICLOALQUILO C3-C6, CARBAMOILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 1-ETIL-3-(5'-(5-METIL-1,3,4-OXADIAZOL-2-IL)-4-(4-(TRIFLUOROMETIL)TIAZOL-2-IL)-3,3'-BIPIRIDIN-6-IL)UREA, 1-(5'-CIANO-4-(4-(4-(TRIFLUOROMETIL)TIAZOL-2-IL)-3,3'-BIPIRIDIN-6-IL)-3-ETILUREA, 1-(5'-(2H-TETRAZOL-5-IL)-4-(4-8TRIFLUOROMETIL)TIAZOL-2-IL)-3,3'-BIPIRIDIN-6-IL)-3-ETILUREA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS INHIBEN LA ADN GIRASA Y/O LA TOPOISOMERASA Y SON UTILES EN EL TRATAMIENTO DE INFECCIONES BACTERIANAS
PE2009000289A 2008-02-26 2009-02-26 Derivados heterociclicos de urea como inhibidores de adn girasa y/o topoisomerasa PE20091573A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3162108P 2008-02-26 2008-02-26

Publications (1)

Publication Number Publication Date
PE20091573A1 true PE20091573A1 (es) 2009-11-12

Family

ID=40474753

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000289A PE20091573A1 (es) 2008-02-26 2009-02-26 Derivados heterociclicos de urea como inhibidores de adn girasa y/o topoisomerasa

Country Status (23)

Country Link
US (1) US20120101100A1 (es)
EP (1) EP2262801A1 (es)
JP (1) JP2011513216A (es)
KR (1) KR20100117681A (es)
CN (1) CN102015699A (es)
AR (1) AR070493A1 (es)
AU (1) AU2009219883A1 (es)
BR (1) BRPI0907562A2 (es)
CA (1) CA2716365A1 (es)
CL (1) CL2009000426A1 (es)
CO (1) CO6290656A2 (es)
CR (1) CR11641A (es)
DO (1) DOP2010000259A (es)
EA (1) EA201001368A1 (es)
EC (1) ECSP10010419A (es)
IL (1) IL207731A0 (es)
MX (1) MX2010009163A (es)
PE (1) PE20091573A1 (es)
SA (1) SA109300138B1 (es)
TW (1) TW200940537A (es)
UY (1) UY31673A1 (es)
WO (1) WO2009106885A1 (es)
ZA (1) ZA201005997B (es)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5581219B2 (ja) 2008-01-25 2014-08-27 ミレニアム ファーマシューティカルズ， インコーポレイテッド チオフェンおよびホスファチジルイノシトール３−キナーゼ（ｐｉ３ｋ）阻害薬としてのその使用
AU2012203026B2 (en) * 2008-03-21 2014-06-12 Novartis Ag Novel heterocyclic compounds and uses thereof
US8865732B2 (en) 2008-03-21 2014-10-21 Novartis Ag Heterocyclic compounds and uses thereof
WO2009147433A1 (en) * 2008-06-04 2009-12-10 Astrazeneca Ab Heterocyclic urea derivatives for the treatment of bacterial infections
WO2010052448A2 (en) * 2008-11-05 2010-05-14 Ucb Pharma S.A. Fused pyrazine derivatives as kinase inhibitors
WO2010054398A1 (en) 2008-11-10 2010-05-14 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
EP2376485B1 (en) 2008-12-19 2017-12-06 Vertex Pharmaceuticals Incorporated Pyrazine derivatives useful as inhibitors of atr kinase
JP2012516329A (ja) 2009-01-30 2012-07-19 ミレニアム ファーマシューティカルズ， インコーポレイテッド Ｐｉ３ｋ阻害剤としてのヘテロアリールおよびその使用
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US9090601B2 (en) * 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
TW201102065A (en) 2009-05-29 2011-01-16 Astrazeneca Ab Heterocyclic urea derivatives and methods of use thereof
FR2953519B1 (fr) * 2009-12-08 2012-02-10 Commissariat Energie Atomique Nouveaux composes chimiques aptes a complexer au moins un element metallique et complexe de coordination a base de ces composes
EP2552893B1 (en) 2010-03-31 2014-10-29 Actelion Pharmaceuticals Ltd. Antibacterial isoquinolin-3-ylurea derivatives
EP2560488B1 (en) 2010-04-23 2015-10-28 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
EP2569289A1 (en) 2010-05-12 2013-03-20 Vertex Pharmaceuticals Incorporated Pyrazines useful as inhibitors of atr kinase
JP2013526538A (ja) 2010-05-12 2013-06-24 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
WO2011143423A2 (en) 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2011143425A2 (en) 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
NZ603478A (en) 2010-05-12 2014-09-26 Vertex Pharma 2 -aminopyridine derivatives useful as inhibitors of atr kinase
MX2012013081A (es) 2010-05-12 2013-05-09 Vertex Pharma Compuestos utiles como inhibidores de cinasa atr.
EP2585468A1 (en) 2010-06-23 2013-05-01 Vertex Pharmaceuticals Incorporated Pyrrolo- pyrazine derivatives useful as inhibitors of atr kinase
AR082665A1 (es) 2010-08-11 2012-12-26 Millennium Pharm Inc Derivados heteroarilicos inhibidores de quinasas pi3k, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos proliferativos, inflamatorios y/o cardiovasculares
WO2012021611A1 (en) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
JP2013533318A (ja) 2010-08-11 2013-08-22 ミレニアム ファーマシューティカルズ， インコーポレイテッド ヘテロアリールおよびその使用
AU2011303597A1 (en) * 2010-09-17 2013-04-11 Purdue Pharma L.P. Pyridine compounds and the uses thereof
TW201307309A (zh) 2010-10-13 2013-02-16 Millennium Pharm Inc 雜芳基化合物及其用途
AR088729A1 (es) 2011-03-29 2014-07-02 Actelion Pharmaceuticals Ltd Derivados de 3-ureidoisoquinolin-8-ilo y una composicion farmaceutica
WO2012138938A1 (en) 2011-04-05 2012-10-11 Vertex Pharmaceuticals Incorporated Aminopyrazine compounds useful as inhibitors of tra kinase
EP2723745A1 (en) 2011-06-22 2014-04-30 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
US9309250B2 (en) 2011-06-22 2016-04-12 Vertex Pharmaceuticals Incorporated Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors
EP2723747A1 (en) 2011-06-22 2014-04-30 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
CA2844865A1 (en) * 2011-09-12 2013-03-21 F. Hoffmann-La Roche Ag 3-pyridine carboxylic acid hydrazides as hdl-cholesterol raising agents
MX2014003785A (es) 2011-09-30 2014-07-24 Vertex Phamaceuticals Inc Tratamiento del cancer de pancreas y del cancer de pulmon de celulas no pequeñas con inhibidores de atr.
ES2751741T3 (es) 2011-09-30 2020-04-01 Vertex Pharma Procedimiento para fabricar compuestos útiles como inhibidores de la quinasa ATR
US8765751B2 (en) 2011-09-30 2014-07-01 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
MX2014003796A (es) 2011-09-30 2015-01-16 Vertex Pharma Compuestos utiles como inhibidores de la cinasa ataxia telangiectasia mutada y rad3 relacionados (atr).
US8853217B2 (en) 2011-09-30 2014-10-07 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
PE20142282A1 (es) * 2011-11-04 2015-01-08 Hoffmann La Roche Nuevos derivados de aril-quinolina
US8846917B2 (en) 2011-11-09 2014-09-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2013071093A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Pyrazine compounds useful as inhibitors of atr kinase
WO2013071094A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2013071085A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Pyrazine compounds useful as inhibitors of atr kinase
WO2013071090A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2013091011A1 (en) * 2011-12-21 2013-06-27 Biota Europe Ltd Heterocyclic urea compounds
CA2869309C (en) 2012-04-05 2021-02-09 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase and combination therapies thereof
US9546155B2 (en) 2012-06-15 2017-01-17 Mitsubishi Tanabe Pharma Corporation Aromatic heterocyclic compound
WO2014055756A1 (en) 2012-10-04 2014-04-10 Vertex Pharmaceuticals Incorporated Method for measuring atr inhibition mediated increases in dna damage
WO2014062604A1 (en) 2012-10-16 2014-04-24 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
EP3808749B1 (en) 2012-12-07 2023-03-08 Vertex Pharmaceuticals Incorporated Pyrazolo[1,5-a]pyrimidines useful as inhibitors of atr kinase for the treatment of cancer diseases
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
US9663519B2 (en) 2013-03-15 2017-05-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
KR20160081898A (ko) 2013-09-06 2016-07-08 오리진 디스커버리 테크놀로지스 리미티드 면역조절제로서 1,3,4-옥사디아졸 및 1,3,4-티아디아졸 유도체
HUE046727T2 (hu) 2013-12-06 2020-03-30 Vertex Pharma Az ATR-kináz inhibitoraként használható vegyület, 2-amino-6-fluoro-N-[5-fluoro-piridin-3-IL]-pirazolo-[1,5-A]-pirimidin-3-karboxamid, ennek elõállítása, különbözõ szilárd formái és ezek radioaktív nyomjelzett származékai
EP3152212B9 (en) 2014-06-05 2020-05-27 Vertex Pharmaceuticals Inc. Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof
JP6936007B2 (ja) 2014-06-17 2021-09-15 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ｃｈｋ１阻害剤とａｔｒ阻害剤との組み合わせを使用してがんを処置する方法
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
CN107427497A (zh) * 2015-03-10 2017-12-01 奥瑞基尼探索技术有限公司 作为免疫调节剂的3‑取代的1,3,4‑噁二唑和噻二唑化合物
AU2016331955B2 (en) 2015-09-30 2022-07-21 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
BR112019005046A2 (pt) 2016-09-19 2019-06-18 Novartis Ag combinações terapêuticas compreendendo um inibidor de raf e um inibidor de erk
CN106866571B (zh) * 2017-01-20 2018-06-29 中国药科大学 杂环脲类化合物及其药物组合物和应用
JPWO2018174288A1 (ja) 2017-03-24 2020-01-23 大正製薬株式会社 ２（１ｈ）−キノリノン誘導体
CN111116559A (zh) * 2018-11-01 2020-05-08 复旦大学 吡啶脲类化合物及其制备方法和制药用途
WO2022147210A1 (en) * 2020-12-31 2022-07-07 Evrys Bio, Llc Anti-tumor compositions and methods

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0014022D0 (en) * 2000-06-08 2000-08-02 Novartis Ag Organic compounds
US7569591B2 (en) * 2003-01-31 2009-08-04 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
AR042956A1 (es) * 2003-01-31 2005-07-13 Vertex Pharma Inhibidores de girasa y usos de los mismos
CA2670870A1 (en) * 2006-12-04 2008-06-12 Astrazeneca Ab Antibacterial polycyclic urea compounds

Also Published As

Publication number Publication date
ECSP10010419A (es) 2010-09-30
JP2011513216A (ja) 2011-04-28
CA2716365A1 (en) 2009-09-03
CO6290656A2 (es) 2011-06-20
IL207731A0 (en) 2010-12-30
AU2009219883A1 (en) 2009-09-03
ZA201005997B (en) 2013-01-30
MX2010009163A (es) 2010-09-14
EP2262801A1 (en) 2010-12-22
TW200940537A (en) 2009-10-01
UY31673A1 (es) 2009-09-30
AR070493A1 (es) 2010-04-07
BRPI0907562A2 (pt) 2017-05-23
DOP2010000259A (es) 2010-09-15
US20120101100A1 (en) 2012-04-26
CR11641A (es) 2010-10-05
KR20100117681A (ko) 2010-11-03
WO2009106885A1 (en) 2009-09-03
CL2009000426A1 (es) 2011-02-11
EA201001368A1 (ru) 2011-04-29
CN102015699A (zh) 2011-04-13
SA109300138B1 (ar) 2012-11-03

Similar Documents

Publication Publication Date Title
PE20091573A1 (es) Derivados heterociclicos de urea como inhibidores de adn girasa y/o topoisomerasa
PE20091842A1 (es) Pirrolidinonas como activadores de glucoquinasa
PE20090773A1 (es) Derivados de morfolina pirimidina
PE20090772A1 (es) Derivados de bencimidazol
PE20142099A1 (es) Derivados de sulfonamida
PE20090601A1 (es) Derivados de piridin-il-oxi-piridinas como inhibidores de alk5
PE20080906A1 (es) Derivados heteroarilo como inhibidores de citocina
PE20070189A1 (es) COMPUESTO DE AMINO-5-HETEROARILO (5 MIEMBROS) IMIDAZOLONA Y SU USO PARA MODULACION DE LA ß-SECRETASA
CO6270320A2 (es) Derivados de piperidina utiles como antagonistas del receptor orexina
PE20090895A1 (es) Derivados de triazol como inhibidores de la jak quinasa
PE20120693A1 (es) Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)
ES2531256T3 (es) Amidas fungicidas
PE20091008A1 (es) Derivados heterociclicos como moduladores de fosfoinositida 3-cinasa
PE20110367A1 (es) DERIVADOS DE 4-CIANO-4-FENIL-PIRROLIDIN-2-CARBOXAMIDAS SUSTITUIDAS COMO INHIBIDORES DE LA INTERACCION p53-MDM2
PE20081836A1 (es) Derivados de piperidina como inhibidores de la sintasa de acido graso
PE20090816A1 (es) Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3
PE20120635A1 (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas
PE20060691A1 (es) Serinamidas sustituidas por benzoilo
PE20150621A1 (es) Derivados de 2,4-diamino-pirimidina n2, n4-disustituidos como inhibidores de jak3
PE20091959A1 (es) Derivados de urea heterociclicos como antibacterianos
PE20110805A1 (es) Compuestos con anillos espiro-triciclicos como moduladores de beta-secretasas y metodos de uso
PE20080608A1 (es) Compuestos quimicos
PE20080418A1 (es) Compuestos y composiciones como moduladores de la via de hedgehog
PE20061130A1 (es) Derivados de 3-fenil-pirazol como moduladores del receptor de serotonina 5-ht2a
PE20090641A1 (es) Amidas heterociclicas

Legal Events

Date Code Title Description
FC Refusal